Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Free Cash Flow (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Free Cash Flow for 6 consecutive years, with $20.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 914.84% year-over-year to $20.0 million, compared with a TTM value of $28.6 million through Dec 2025, up 177.41%, and an annual FY2025 reading of $28.6 million, up 177.41% over the prior year.
  • Free Cash Flow was $20.0 million for Q4 2025 at Xeris Biopharma Holdings, up from $18.4 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $20.0 million in Q4 2025 and bottomed at -$48.4 million in Q1 2022.
  • Average Free Cash Flow over 5 years is -$12.7 million, with a median of -$15.4 million recorded in 2022.
  • The sharpest move saw Free Cash Flow crashed 162.1% in 2021, then skyrocketed 914.84% in 2025.
  • Year by year, Free Cash Flow stood at -$29.1 million in 2021, then surged by 44.56% to -$16.1 million in 2022, then soared by 146.35% to $7.5 million in 2023, then plummeted by 73.56% to $2.0 million in 2024, then surged by 914.84% to $20.0 million in 2025.
  • Business Quant data shows Free Cash Flow for XERS at $20.0 million in Q4 2025, $18.4 million in Q3 2025, and $182000.0 in Q2 2025.